J0893 HCPCS code: Injection, decitabine (sun pharma), not therapeutically equivalent to j0894, 1 mg
J0893 is the HCPCS Level II code for injection, decitabine (sun pharma), not therapeutically equivalent to j0894, 1 mg. In 2023 Medicare paid an average of $1.35 per service for J0893 across 3,726 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. In 2023, about 29 clinicians billed Medicare for J0893 for 21 beneficiaries.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2023-01-01 |
| Last action effective | 2024-07-01 |
Who bills J0893 (2023)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 29 |
| Medicare beneficiaries | 21 |
| States with claims | 0 |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J0893, 2023–2023
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2023 | 3,726 | 21 | $1.72 | $1.35 |
What changed for J0893
- 2023-01-01: J0893 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J0893?
J0893 is the HCPCS Level II code for injection, decitabine (sun pharma), not therapeutically equivalent to j0894, 1 mg. Short descriptor: "Inj, decitabine (sun pharma)".
How much does Medicare pay for J0893?
In 2023, the average Medicare payment was $1.35 per service (average allowed $1.72).
Does Medicare cover J0893?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
Related J08 codes
- J0800 — Injection, corticotropin, up to 40 units
- J0801 — Injection, corticotropin (acthar gel), up to 40 units
- J0802 — Injection, corticotropin (ani), up to 40 units
- J0833 — Injection, cosyntropin, not otherwise specified, 0.25 mg
- J0834 — Injection, cosyntropin, 0.25 mg
- J0840 — Injection, crotalidae polyvalent immune fab (ovine), up to 1 gram
- J0841 — Injection, crotalidae immune f(ab')2 (equine), 120 mg
- J0850 — Injection, cytomegalovirus immune globulin intravenous (human), per vial
- J0870 — Injection, imetelstat, 1 mg
- J0872 — Injection, daptomycin (xellia), unrefrigerated, not therapeutically equivalent to j0878 or j0873, 1 mg
- J0873 — Injection, daptomycin (xellia), not therapeutically equivalent to j0878 or j0872, 1 mg
- J0874 — Injection, daptomycin (baxter), not therapeutically equivalent to j0878, 1 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J0893
- Watch J0893 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J0893
Sources: CMS HCPCS Level II release October 2025; CMS DMEPOS fee schedule; CMS NCCI MUE tables; CMS Medicare utilization (physician and DME supplier files); CMS Medicare Coverage Database articles. Fees are Medicare allowables, not commercial rates. Not billing or legal advice.